Physician profile
Merwin Moore
NPI 1386617561
$2,329.34
in general payments reported to CMS, 2019-2025
12 companies · $31.41 in 2025
The $31.41 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $231 · 2021: $297 · 2022: $59.87 · 2023: $404 · 2024: $98.15 · 2025: $31.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331 · Travel and Lodging: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.09 |
| Travel and Lodging | $202.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,387.42 | 2019-2023 | Rosa |
| Stryker Corporation | $244.10 | 2019-2025 | Mako, Gamma, Variax |
| Pacira Therapeutics, INC. | $205.65 | 2019-2021 | |
| Amgen INC. | $139.72 | 2019-2022 | |
| Radius Health, INC. | $86.74 | 2019-2021 | |
| Heraeus Medical, LLC. | $56.31 | 2021 | |
| Smith+Nephew, INC. | $48.43 | 2019-2021 | |
| Baudax Bio INC. | $40.85 | 2021 | |
| Teleflex LLC | $39.14 | 2023 | Quikclot |
| Bioventus LLC | $36.69 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $34.65 | 2022 | |
| Orthofix Medical, INC. | $9.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merwin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.